Payment overview · 2025
General Payments
$320.62
18 reported records · 10 companies
Healthcare provider profile · identity verified
Robert E Mcclure, MD
Allopathic & Osteopathic Physicians|Family Medicine · CANEYVILLE, KY · NPI 1447253786
Verified facts
What the public records show
CMS Open Payments records show Robert E Mcclure, MD received $320.62 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.32 | 24.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.44 | 16.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.25 | 15.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.69 | 9.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$30.92 | 9.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.40 | 5.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.61 | 5.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.37 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.49 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.13 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.62 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.32 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.32 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.44 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.44 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $30.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 633 | 70 |
| Gabapentin | Gabapentin | 468 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 398 | 80 |
| Omeprazole | Omeprazole | 375 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 71 |
| Lisinopril | Lisinopril | 351 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 72 |
| Furosemide | Furosemide | 333 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 57 |
| Simvastatin | Simvastatin | 241 | 47 |
| Metformin Hcl Er | Metformin Hcl | 215 | 40 |
| Potassium Chloride | Potassium Chloride | 212 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 191 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 40 |
| Atenolol | Atenolol | 161 | 34 |
| Celecoxib | Celecoxib | 160 | 31 |
| Eliquis | Apixaban | 160 | 32 |
| Jardiance | Empagliflozin | 157 | 31 |
| Metformin Hcl | Metformin Hcl | 153 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 39 |
| Alprazolam | Alprazolam | 150 | 18 |
| Montelukast Sodium | Montelukast Sodium | 135 | 25 |
| Spironolactone | Spironolactone | 135 | 25 |
| Clonazepam | Clonazepam | 124 | 20 |
| Sertraline Hcl | Sertraline Hcl | 120 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 119 | 22 |
| Diazepam | Diazepam | 117 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 117 | 23 |
| Farxiga | Dapagliflozin Propanediol | 116 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 30 |
| Ozempic | Semaglutide | 110 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 31 |
| Carvedilol | Carvedilol | 105 | 24 |
| Tramadol Hcl | Tramadol Hcl | 103 | 17 |
| Doxepin Hcl | Doxepin Hcl | 97 | 20 |
| Baclofen | Baclofen | 88 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 12 |
| Trazodone Hcl | Trazodone Hcl | 83 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 14 |
| Meclizine Hcl | Meclizine Hcl | 79 | 24 |
| Allopurinol | Allopurinol | 77 | 15 |
| Promethazine Hcl | Promethazine Hcl | 76 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 18 |
| Famotidine | Famotidine | 73 | 15 |
| Naproxen | Naproxen | 73 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 15 |
| Meloxicam | Meloxicam | 69 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 63 | 15 |
| Finasteride | Finasteride | 62 | 19 |
| Losartan Potassium | Losartan Potassium | 60 | 18 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | suppressed |
| Ibuprofen | Ibuprofen | 58 | 13 |
| Azithromycin | Azithromycin | 57 | 46 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Ezetimibe | Ezetimibe | 56 | suppressed |
| Mirtazapine | Mirtazapine | 55 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Prednisone | Prednisone | 54 | 28 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Linzess | Linaclotide | 49 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Nystatin | Nystatin | 44 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Glipizide | Glipizide | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Digoxin | Digoxin | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 32 |
| Nitroglycerin | Nitroglycerin | 34 | 21 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 30 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Primidone | Primidone | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Zafirlukast | Zafirlukast | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Hydrocortisone | Hydrocortisone | 17 | 12 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Asmanex | Mometasone Furoate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Imipramine Pamoate | Imipramine Pamoate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $320.62 · 18 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, ENDURANT IIS, FARXIGA, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, YUPELRI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error